Brief: Medexus Pharmaceuticals Says Entered Into Commercialization & Supply Agreement With Medac

Medexus Pharmaceuticals

02/02/2021 19:27

Feb 2 (Reuters) - Medexus Pharmaceuticals Inc  MDP.V :
    * MEDEXUS PHARMACEUTICALS - CO, U.S. UNIT ENTERED INTO
COMMERCIALIZATION & SUPPLY AGREEMENT WITH MEDAC
    * MEDEXUS PHARMACEUTICALS - MEDAC HAS GRANTED MEDEXUS PHARMA
EXCLUSIVE LICENSE TO COMMERCIALIZE TREOSULFAN IN U.S.
    * MEDEXUS PHARMACEUTICALS - PDUFA DATE TO REVIEW NDA IN
RESPECT OF
TREOSULFAN BY FDA HAS BEEN SCHEDULED FOR AUGUST 2021
    * MEDEXUS PHARMACEUTICALS INC - UPON ENTERING INTO LICENSE
AGREEMENT, MEDEXUS PHARMA PAID MEDAC A NON-REFUNDABLE UPFRONT
PAYMENT OF U.S. $5 MILLION
    * MEDEXUS PHARMACEUTICALS - UNDER TERMS, MEDEXUS PHARMA TO
PAY
MEDAC UP TO $55 MILLION IN NON-REFUNDABLE REGULATORY MILESTONE
PAYMENTS
    * MEDEXUS PHARMACEUTICALS - UNDER TERMS, MEDEXUS PHARMA TO
PAY
MEDAC UP TO $40 MILLION IN NON-REFUNDABLE SALES MILESTONE
PAYMENTS
    * MEDEXUS PHARMACEUTICALS - MEDEXUS PHARMA TO PAY MEDAC A
LOW
SINGLE-DIGIT ROYALTY ON ITS NET SALES OF TREOSULFAN IN U.S.

Source text for Eikon:  ID:nGNX11mpHm 
Further company coverage:  MDP.V 

 ((Reuters.Briefs@thomsonreuters.com;))